AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large ...

AbbVie leads a Zacks Analyst Blog roundup highlighting strong pharma execution, AI-driven chip gains and an aviation rebound.

AbbVie agreed to lower Medicaid prices and invest $100 billion in the US in exchange for tariff and pricing relief.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbbVie (ABBV – Research Report) and Glaukos (GKOS – Research Report) with bull ...

AbbVie agrees to lower drug prices, invest $100 billion in the U.S., expand manufacturing, and secure tariff relief.

According to TipRanks.com, Gerberry is a 5-star analyst with an average return of 15.5% and a 61.7% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Harmony Biosciences ...

AbbVie's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Learn more ...

Shares of AbbVie Inc. ABBV slipped 3.98% to $220.18 Monday, on what proved to be an all-around great trading session for the ...

AbbVie slides after the company cut guidance, Wolfe Research downgraded the stock and the company pushed back on acquisition reports ...

Abbvie Inc. signed a $1.1 billion New Year’s Eve deal with China’s Zelgen Biopharmaceuticals Co. Ltd., gaining ex-China ...

Abbvie Inc. announced its agreement to focus on improving access and lowering the cost of medicines, becoming the latest pharma to fall in line with the Trump administration’s most-favored nation (MFN ...